ciclopirox topical / Generic mfg. - LARVOL DELTA

Design, synthesis and antiviral activity of ciclopirox (CPX) analogs against orthopoxvirus. (PubMed, Bioorg Med Chem) - "In the end, the SAR identified one analog (5h, EC50 = 0.12 μM) showing substantially improved antiviral activity over CPX (EC50 = 0.51 μM), and numerous analogs exhibiting strong antiviral activities (EC50 = 0.71-1.2 μM) comparable to CPX without significant cytotoxicity. These SAR trends and additional potent analogs identified provide a strong foundation for future optimization efforts."

Journal

Brazilin attenuates methylglyoxal‑induced endothelial injury by enhancing eIF5A hypusination and inhibiting the AMPK/mTOR‑mediated autophagy/apoptosis axis in vitro and in vivo. (PubMed, Int J Mol Med) - "By contrast, ciclopirox, a specific inhibitor of DOHH, abolished the BZ‑mediated suppression of MGO‑induced cellular responses...Using db/db mice to mimic the diabetic microenvironment, it was further found that DOHH inhibition reversed the BZ‑mediated suppression of autophagy and apoptosis. Collectively, the findings of the present study reveal a DOHH/eIF5A‑AMPK/mTOR axis through which BZ antagonizes MGO‑induced autophagy and apoptosis, shedding new light on the pharmacological mechanism of BZ and underscoring its therapeutic potential for diabetic vascular complications."

Journal • Preclinical • Diabetes • Inflammation • Metabolic Disorders • AMPK

Lipid Nanoparticle Co-Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy. (PubMed, Adv Mater) - "To overcome these obstacles, we employed a lipid nanoparticle (LNP) that co-encapsulates p53 mRNA and the small molecule ciclopirox (CPX)...When formulated together, our platform provides an all-in-one approach for OSCC, effective in both p53-therapy-susceptible and p53-therapy-resistant models. Additionally, this work offers a template for a delivery platform capable of tackling multiple mechanisms of OSCC progression and survival."

IO biomarker • Journal • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma

Ciclopirox suppresses melanoma growth by activating ER stress-driven apoptosis and disrupting Src/STAT3 signaling. (PubMed, Acta Biochim Biophys Sin (Shanghai)) - "This apoptotic process is rescued by the antioxidant N-acetylcysteine, supporting a causative role of oxidative stress in CPX-induced cytotoxicity. It also downregulates total STAT3 protein levels and Ser727 phosphorylation, indicating multi-level disruption of STAT3 signaling. In conclusion, our findings reveal that CPX suppresses melanoma through dual mechanisms: activating ROS/ER stress-mediated apoptosis and disrupting the Src/STAT3 signaling pathway, supporting its therapeutic repurposing for melanoma."

Journal • Melanoma • Metabolic Disorders • Oncology • Solid Tumor • CASP3

Sustained Use of Topical Tacrolimus for Seborrhoeic Dermatitis: Revisiting Cancer Risk in Light of Chronic Inflammatory Control – A Meta-Analysis (BAD 2026) - "Randomized controlled trials demonstrated that tacrolimus 0.1% is at least noninferior to low-potency corticosteroids and ciclopirox for facial SD, with superior relapse prevention and reduced application frequency in proactive regimens. Topical tacrolimus is an effective, well-tolerated and genuinely steroid-sparing long-term therapy for SD, including on cosmetically sensitive facial sites. Contemporary high-quality evidence does not support an increased malignancy risk with sustained topical use, challenging current prescribing hesitancy and supporting guideline-level endorsement as a frontline or maintenance option in chronic SD."

Retrospective data • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Genetic Disorders • Hematological Malignancies • Immunology • Lymphoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • T Cell Non-Hodgkin Lymphoma

Mass Spectrometry-Based Screening Reveals Inhibitors of Cholesterol 25-Hydroxylase. (PubMed, ACS Chem Biol) - "Screening of this assay across a focused library of over 100 small molecules containing either an iron-coordinating moiety or a sterane ring system revealed three potent inhibitors of cellular CH25H activity (U73343, Ciclopirox, and phenanthroline)...Finally, U73343 but not the iron-binding hits showed strong selectivity versus related diiron lipid oxidases. Overall, our work establishes a series of cell-based assays monitoring CH25H function and nominates first-in-class cell-active inhibitors of this disease-relevant enzyme."

Journal • Alzheimer's Disease • CNS Disorders • Immunology • Osteoarthritis • Pain • Rheumatology

Combination therapy using Ciclopirox and Salicylic acid incorporated Chitosan lotion for onychomycosis treatment. (PubMed, Int J Biol Macromol) - "In vivo antifungal activity in Drosophila melanogaster fly model validated the in vivo safety of the developed CSL-SA-CX against C. albicans. Thus, the prepared CSL-SA-CX lotion can be used to treat Onychomycosis as well as a wide range of nail fungal infections."

Journal • Infectious Disease • Pain

Ciclopirox reprograms effector responses and modulates Notch1 activation in activated human T cells. (PubMed, iScience) - "The prodrug of CPX, fosciclopirox, was evaluated for safety and preliminary efficacy in patients with advanced solid tumors, including bladder cancer, and was found to inhibit cell proliferation, the γ-secretase complex, and Notch signaling. Mechanistically, CPX modulates Notch1 activation temporally and reprograms T cell metabolism by limiting glycolysis, both of which impact proliferative and effector responses in activated T cells. Together, these findings identify CPX as a modulator of T cell immunity, highlighting the broader immunologic implications for its therapeutic application."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • IFNG • IL2 • NOTCH1

Preliminary Functional Screening of Autochthonous Saccharomyces cerevisiae from Mexican Cocoa Bean Fermentation for Traits Associated with Probiotic Potential. (PubMed, Microorganisms) - "Evaluated parameters included tolerance to temperature, pH, and bile salts; hemolytic activity; survival in vitro under gastrointestinal (GI) conditions; bile salt hydrolase activity; auto-aggregation; co-aggregation; hydrophobicity; and response to antifungal agents (fluconazole, ciclopirox, nystatin, and clotrimazole). Therefore, the studied yeast strains should be regarded as preliminary candidates requiring further validation. This work provides a first-stage evaluation for identifying functional yeast strains from Mexican cocoa bean fermentation, serving as a basis for future in vitro and in vivo studies."

Journal • Gastrointestinal Disorder

Healthcare utilization and treatment patterns in patients with seborrheic dermatitis: A retrospective cohort study (SID 2026) - "Of patients filling prescriptions, most filled prescriptions were ketoconazole (70%), hydrocortisone (22%), clobetasol (12%), and ciclopirox (5%). Ketoconazole is the preferred prescription treatment for seb derm. The absence of established efficacy differences within the antifungal class and between topical antifungals and topical steroids suggests that something other than efficacy is driving the preference for ketoconazole. The high volume of antifungal prescriptions raises concern for antifungal resistance."

HEOR • Retrospective data • Dermatitis • Dermatology • Immunology • Inflammation • Seborrheic Dermatitis

Response to Reich and Lipner, "Defining an onychomycosis cohort: The importance of mycologic sampling". (PubMed, JAAD Int) - No abstract available

Journal • Infectious Disease

Therapeutic Advances in Head and Neck Dermatitis (HND): A Clinical Update (AAD 2026) - " Selective JAK1 inhibitors, including upadacitinib and abrocitinib, achieve rapid and sustained clearance in dupilumab-refractory cases, while topical delgocitinib and roxolitinib have shown benefits without local adverse effects. IL-13 antagonists such as tralokinumab and lebrikizumab provided head-to-neck symptomatic and quality-of-life improvement in patients unresponsive to dupilumab or JAK inhibitors, with a favorable safety profile...Topical agents like ketoconazole and ciclopirox showed good tolerability and clinical improvement in mild cases. Oral itraconazole, while favored for its lipophilic properties and ability to reduce Malassezia-specific IgE, was often followed by relapse upon discontinuation... HND represents a distinct, treatment-resistant AD phenotype requiring strategic multimodal care. Immunomodulators and antifungal therapies, often combined with topical agents, offer promising results, though larger long-term trials are needed to define optimal..."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL13

Activity of Topical Antifungals Against the Terbinafine-Resistant Dermatophyte Trichophyton indotineae: In Vivo Analysis (AAD 2026) - "These results were confirmed in this in vivo model of T. indotineae dermatophytosis, in which efinaconazole demonstrated clinical efficacy 1.6- and ~3-fold higher than tavaborole and ciclopirox, respectively. These findings suggest efinaconazole may be effective in treatment of onychomycosis from terbinafine-resistant T. indotineae."

Preclinical • Infectious Disease

Nail tattooing: a novel and minimally invasive technique for enhancing drug penetration through the nail. (PubMed, Drug Deliv Transl Res) - "Ciclopirox olamine and clobetasol lacquers were selected as the model formulations. Drug permeation tests conducted on non-treated, filed (mechanically abraded), and tattooed nails demonstrated significantly higher drug permeation in tattooed nails, suggesting the potential of this delivery method. Nail tattooing offers a simple method to enhance topical therapy, allowing treatment initiation in the clinic and continuation at home."

Journal • Dermatology • Immunology • Infectious Disease • Psoriasis

FDA-approved drug library screen identifies antidepressants, antimicrobials, anti-COPD, and anti-CVD agents as blockers of NLRP3 inflammasome and sepsis in a sex-dependent manner. (PubMed, bioRxiv) - "Various classes of drugs, such as antidepressants (Fluoxetine, Duloxetine), antihypertensives (Irbesartan, amlodipine, nebivolol), antidiabetics (Rosiglitazone), β-adrenergic agonists (Salmeterol), antimalarials (Mefloquine), antifungals (Azoles, ciclopirox), and antivirals (Saquinavir, Remdesivir), were identified as potent blockers of either priming or assembly of NLRP3 inflammasome. Mice treated with LPS-priming blockers showed a sex-specific increase in survival rate in the mouse model of LPS-induced mortality, validating the in vitro screen. Further studies in primary human cells and in vivo disease models are needed to assess the repurposing and therapeutic relevance of identified drugs."

FDA event • Journal • Alzheimer's Disease • Asthma • Chronic Obstructive Pulmonary Disease • CNS Disorders • Diabetes • Genetic Disorders • Gout • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Movement Disorders • Novel Coronavirus Disease • Obesity • Parkinson's Disease • Pulmonary Disease • Respiratory Diseases • Rheumatology • Septic Shock • NLRP3

ATL001-PII-CEP: A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP (clinicaltrials.gov) - P1/2 | N=6 | Recruiting | Sponsor: Atlas Molecular Pharma | Trial completion date: Nov 2027 ➔ Jun 2028 | Trial primary completion date: Oct 2027 ➔ May 2028

Trial completion date • Trial primary completion date • Genetic Disorders • Hematological Disorders • Metabolic Disorders • Rare Diseases

Tinea Capitis in a 4-Week-Old Infant (AAD 2026) - "She was treated with topical ciclopirox 0.77% cream applied twice daily and ketoconazole 2% shampoo used daily, leading to clinical resolution over 4 weeks without adverse effects. Early recognition allows prompt treatment and prevention of spread. While systemic antifungals are standard in older children, this case demonstrates that topical therapy can be an effective option in neonates when systemic therapy is not feasible."

Dermatology • Infectious Disease

Effect of the antifungal drug ciclopirox on the inhibition of HMGA2-mediated oncogenic capacity in ACHN renal cell carcinoma. (PubMed, Front Pharmacol) - "The TGF-β/Smads signaling pathway is linked to this phenomenon. These results provide robust evidence highlighting the potential for repurposing CPX in cancer treatment."

Journal • Genito-urinary Cancer • Infectious Disease • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CCND1 • CDK6 • E2F1 • HMGA2 • TGFB1

Evaluation of In Vitro Efficiency of Ciclopirox Against Yersinia pestis and Francisella tularensis. (PubMed, Int J Mol Sci) - "Our findings reveal that ciclopirox effectively inhibits the in vitro growth of fully virulent strains of Y. pestis and F. tularensis, as well as avirulent isolates, including avirulent mutants that their wild-type susceptibility was reduced through selection to MIC levels defining them as "nonsusceptible" to ciprofloxacin (Y. pestis Kim53Δ70Δ10 and F. tularensis LVS) and doxycycline (LVS), or resistant to doxycycline (Kim53Δ70Δ10) according to CLSI interpretive criteria. Additionally, prolonged exposure of Y. pestis and F. tularensis to sub-MIC and MIC concentrations of ciclopirox did not lead to an increase in observed MIC during the study period. These results highlight ciclopirox as a potential candidate for treatment alternative, combined with other antibiotic substances or repurposed drugs against these bacterial threats."

Journal • Preclinical • Infectious Disease

Telemedicine visits for new onychomycosis diagnoses result in fewer antifungal prescriptions than in-person care: A retrospective cohort study. (PubMed, JAAD Int) - No abstract available

Journal • Retrospective data • Infectious Disease

ATL001-PII-CEP: A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP (clinicaltrials.gov) - P1/2 | N=6 | Recruiting | Sponsor: Atlas Molecular Pharma | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Hematological Disorders • Metabolic Disorders • Rare Diseases

Lipid nanoparticle co-delivery of mRNA and a small molecule drug for oral cancer chemoimmunotherapy. (PubMed, bioRxiv) - "To overcome these obstacles, we employed a lipid nanoparticle (LNP) that co-encapsulates p53 mRNA and the small molecule ciclopirox (CPX)...When formulated together, our platform provides an all-in-one approach for OSCC, effective in both p53-therapy-susceptible and p53-therapy-resistant models. Additionally, this work provides a template for a delivery platform capable of tackling multiple mechanisms of OSCC progression and survival."

IO biomarker • Journal • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma

Ciclopirox, a broad-spectrum antifungal drug, moonlights as a pyroptosis agonist to drive hepatocellular carcinoma cell death. (PubMed, Eur J Pharmacol) - "In conclusion, CPX exerts its antitumour effects on HCC through ROS-dependent NLRP3-mediated pyroptosis. This study provides a strong rationale for further clinical exploration and development of CPX-based therapies, offering a promising avenue for improving outcomes in patients with HCC."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • NLRP3

Genomic insights into ST85 and ST158 belonging to recently emerged global clones of multidrug-resistant Acinetobacter baumannii isolates from Egypt: in vitro assessment of repurposed drug-antibiotic combinations. (PubMed, Ann Clin Microbiol Antimicrob) - "The current study provides an in-depth characterization of the collected MDRAB isolates from the global clones GC9 and GC10. The endemicity of these clones necessitates strategies to mitigate ongoing MDRAB outbreaks in countries like Egypt. Combination of NAC with meropenem or levofloxacin represents a promising treatment option against the newly emerged global clones that needs further in vivo testing."

Journal • Preclinical • Infectious Disease

Construction and accuracy assessment of an efferocytosis-related prognostic model for ovarian cancer: A diagnostic accuracy study. (PubMed, Medicine (Baltimore)) - "Notably, AFLATOXIN B1 exhibited strong binding affinity to SLC25A45, ciclopirox to BTN3A3, and irinotecan to WDR91. Additionally, significant differences in the IC50 values of 123 anticancer drugs were observed between the 2 risk groups. This findings of this study highlight the efficacy of the efferocytosis-associated risk model in predicting the survival outcomes of OC patients, thus providing a novel reference for prognostic prediction in OC patients."

Biomarker • IO biomarker • Journal • Tumor mutational burden • Oncology • Ovarian Cancer • Solid Tumor • BTNL3 • FCGBP • TMB